Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Chronic Kidney Disease

Chronic Kidney Disease Medicines in India: Imported Options by Cause and Complication

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERChronic kidney disease (CKD) means the kidneys have been damaged, or have filtered less blood than they should, for three months or more. A Global Burden of Disease analysis counted about 115 million people with CKD in India in 2017 [1], and a national registry found that nearly half of Indian patients first reach a kidney doctor only at stage 5 [3]. Some newer medicines, for anaemia and itch in people on dialysis, and for kidney diseases such as IgA nephropathy and lupus nephritis, are cleared abroad but missing from Indian chemist shelves. With a nephrologist's prescription, Named Patient Program (NPP) can arrange 9 of them, each one imported in the name of a single patient.
11.5 crore
people in India had chronic kidney disease in 2017 (115.1 million); India and China together held almost a third of the 697.5 million cases counted worldwide
Source: GBD 2017 CKD study [1]
17.2%
of 5,588 adults screened at 13 Indian medical centres had CKD, and roughly 6% were already at stage 3 or beyond
Source: SEEK-India study [2]
48%
of 52,273 adults in the Indian CKD Registry were at stage 5 when first recorded
Source: Indian CKD Registry [3]
31%
of registry patients had kidney damage from diabetes, the leading cause; 16% had no cause that doctors could find
Source: Indian CKD Registry [3]

What chronic kidney disease means, stage by stage

Doctors stage CKD with two simple tests: a blood creatinine value, which is turned into an eGFR (how many millilitres of blood the kidneys clean each minute), and a urine test for protein. Early stages often cause no symptoms at all, which is why the disease is usually found late. The stage bands below follow the KDIGO system used by the US National Kidney Foundation [6].

StageeGFR (mL/min/1.73 m²)What it usually means for the patient
1 and 290 or more, then 60 to 89Kidney damage (such as protein in urine) with filtering still near normal; control of sugar and blood pressure matters most
3a and 3b45 to 59, then 30 to 44Filtering clearly reduced; anaemia and bone-mineral changes may start
415 to 29Severe loss; the team begins planning for dialysis or a transplant
5Below 15, or on dialysisKidney failure; dialysis or a transplant is needed to stay well

Who gets CKD in India, and why it is found late

Indian data paint a clear picture. In the SEEK-India screening study, 17.2% of adults tested had CKD, and 79.5% of those with CKD had protein in the urine [2]. The Indian CKD Registry, which enrolled 52,273 adults from all four zones of the country, found [3]:

  • Diabetes was behind 31% of cases, followed by CKD of unknown cause (16%), long-standing glomerulonephritis (14%) and high blood pressure (13%).
  • About 48% of patients were already at stage 5 when they were registered.
  • Patients with CKD of unknown cause were younger, poorer and more often at stage 5; patients from lower income groups also tended to arrive with more advanced disease.

Glomerular diseases, where the tiny filters of the kidney are inflamed or scarred, are a large share of the younger patients. In 3,275 kidney biopsies read at AIIMS New Delhi between 2006 and 2016, the most common filter diseases were FSGS (18.2%), minimal change disease (16.8%), membranous nephropathy (16.0%) and IgA nephropathy (10.4%), while lupus nephritis made up 10.6% [4]. In that series, 60.9% of people whose CKD had no known cause turned out to have a glomerular disease on biopsy [4]. A biopsy report is therefore often the document that decides which of the medicines below can be considered.

Two kinds of help: treating the cause, and easing the complications

The medicines on this page fall into two groups. The first group works on the kidney disease itself, aiming to cut protein loss in the urine or slow the fall in eGFR: Filspari and Fabhalta for IgA nephropathy, Filspari for FSGS, Fabhalta for C3 glomerulopathy, Benlysta for lupus nephritis, and Oxlumo and Cystagon for two inherited conditions that damage the kidneys from childhood. The second group treats problems that come with advanced CKD: Evrenzo and Pegmolesatide raise haemoglobin in kidney anaemia, and Korsuva and Anrikefon calm the stubborn itch many people feel on haemodialysis. None of them replaces dialysis, a transplant, or the basic care of blood pressure, sugar and diet that your nephrologist plans.

Imported chronic kidney disease medicines by type

All 9 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Evrenzo (roxadustat)
Evrenzo
roxadustat · Tablet
Adults whose CKD has caused anaemia with symptoms; a tablet that prompts the body to make more of its own erythropoietin
Anaemia of CKD EMA (Europe)
Pegmolesatide (pegmolesatide)
Pegmolesatide
pegmolesatide · Injection (once a month)
CKD anaemia in adults, either not on dialysis and new to erythropoietin-type medicines, or on dialysis and switching from a short-acting erythropoietin
Anaemia of CKD China NMPA
Korsuva (difelikefalin)
Korsuva
difelikefalin · IV injection after dialysis
Moderate or severe itch caused by CKD in adults treated with haemodialysis (not studied in peritoneal dialysis)
Dialysis itch US FDA
Anrikefon (anrikefon)
Anrikefon
anrikefon · Injection
Moderate or severe CKD-related itch in adults on regular haemodialysis
Dialysis itch China NMPA
Filspari (sparsentan)
Filspari
sparsentan · Tablet
Slows the fall in kidney function in adults who have primary IgA nephropathy and a risk of worsening; lowers urine protein in FSGS without nephrotic syndrome from age 8
IgA nephropathyFSGS US FDA
Fabhalta (iptacopan)
Fabhalta
iptacopan · Capsule
Slows kidney function loss in adults who have primary IgA nephropathy likely to progress, and lowers urine protein in adults with C3 glomerulopathy (also approved for PNH)
IgA nephropathyC3G US FDA
Benlysta (belimumab)
Benlysta
belimumab · IV infusion or injection under the skin
Active lupus nephritis in patients aged 5 and above, added to the standard treatment they already receive
Lupus nephritis US FDA
Oxlumo (lumasiran)
Oxlumo
lumasiran · Injection under the skin
Primary hyperoxaluria type 1 in children and adults, to bring down oxalate in urine and blood
Inherited kidney disease US FDA
Cystagon (cysteamine bitartrate)
Cystagon
cysteamine bitartrate · Capsule
Nephropathic cystinosis, a rare inherited disease, in both children and adults, as long-term treatment
Inherited kidney disease US FDA

Compare all 9 chronic kidney disease medicines

MedicineGeneric nameChronic kidney disease typeFormApproved by
EvrenzoroxadustatAnaemia of CKDTabletEMA (Europe)
PegmolesatidepegmolesatideAnaemia of CKDInjection (once a month)China NMPA
KorsuvadifelikefalinDialysis itchIV injection after dialysisUS FDA
AnrikefonanrikefonDialysis itchInjectionChina NMPA
FilsparisparsentanIgA nephropathy, FSGSTabletUS FDA
FabhaltaiptacopanIgA nephropathy, C3GCapsuleUS FDA
BenlystabelimumabLupus nephritisIV infusion or injection under the skinUS FDA
OxlumolumasiranInherited kidney diseaseInjection under the skinUS FDA
Cystagoncysteamine bitartrateInherited kidney diseaseCapsuleUS FDA

Reports your nephrologist will ask for

Each approval below is tied to a specific diagnosis or treatment situation, so these papers usually come before a prescription is written.

ReportWhat it shows the doctorRelated medicines
Kidney biopsy reportConfirms IgA nephropathy, FSGS, C3 glomerulopathy or the class of lupus nephritisFilspari, Fabhalta, Benlysta
Urine protein (UPCR or 24-hour protein) and eGFR trendShows the risk of the kidney disease getting worse, and later whether the medicine is workingFilspari, Fabhalta, Benlysta
Haemoglobin, iron studies and current anaemia treatmentPegmolesatide's China approval depends on dialysis status and on earlier erythropoietin useEvrenzo, Pegmolesatide
Dialysis type and itch scoreKorsuva is for adults on haemodialysis and has not been studied in peritoneal dialysisKorsuva, Anrikefon
Liver tests (Filspari) and vaccination record (Fabhalta)Filspari needs regular liver checks; Fabhalta needs vaccines against certain bacteria at least 2 weeks before the first dose, unless the doctor decides waiting is riskierFilspari, Fabhalta
Genetic test or urine and plasma oxalate, white-cell cystine levelConfirms primary hyperoxaluria type 1 or nephropathic cystinosisOxlumo, Cystagon

Paperwork, getting the medicine to the dialysis unit, and cost

An imported medicine like these is allowed in for one named patient only. The patient is the one who applies, on Form 12A, which our pharmacist fills in from the prescription, and the patient receives a Form 12B permit from CDSCO; the paperwork checklist is in our Form 12A and 12B guide. Korsuva is injected into the dialysis line at the end of each haemodialysis session, Anrikefon is also given by the dialysis team, and Benlysta is often given as a drip, so these can go straight to the treating hospital through our hospital delivery service.

Kidney medicines are usually long-term, sometimes lifelong. To find help with the bills, see our patient support and access programs, which covers company assistance, state and central health schemes, and charitable trusts.

How to get these chronic kidney disease medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about chronic kidney disease

References

  1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733 (Table 2, India). https://pubmed.ncbi.nlm.nih.gov/32061315/
  2. Singh AK et al. Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK study. BMC Nephrol. 2013;14:114. https://pubmed.ncbi.nlm.nih.gov/23714169/
  3. Rajapurkar MM et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012;13:10. https://pubmed.ncbi.nlm.nih.gov/22390203/
  4. Mittal P et al. Spectrum of biopsy-proven renal disease in northern India: a single-centre study. Nephrology (Carlton). 2020;25(1):55-62. https://pubmed.ncbi.nlm.nih.gov/30834630/
  5. Biswas D et al. Presentation and outcome of pediatric lupus nephritis from a large single centre contemporary cohort in Eastern India. Lupus. 2023;32(12):1440-1446. https://pubmed.ncbi.nlm.nih.gov/37707867/
  6. National Kidney Foundation. Stages of chronic kidney disease (CKD). https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd
  7. US FDA prescribing information for each US-approved medicine (DailyMed). https://dailymed.nlm.nih.gov/dailymed/

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Chronic Kidney Disease Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP